Combined cyclosporine A and urolithin A therapy ameliorates murine lupus nephritis
The Journal of Immunology · 15.04.2026 · 215 (4)
DOI: 10.1093/jimmun/vkag087 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Immunology, online erschienen am 13.05.2026. Verfasst von R Ganugula und 10 weiteren Autor:innen. Beteiligte Einrichtung: The Center for Convergent Bioscience and Medicine (CCBM), The University of Alabama, Tuscaloosa, Alabama, 35487, United States. Hauptthemen laut MEDLINE: Lupus Nephritis, Cyclosporine, Immunosuppressive Agents, Coumarins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Monotherapies for lupus nephritis (LN) often fail to fully control the disease’s hallmark, renal inflammation and immune complex deposition. This study investigates a novel combination therapeutic strategy using urolithin A (UA), a multifaceted anti-inflammatory and antioxidant agent, with cyclosporine A (CsA), an established immunosuppressant. The combination therapy’s superior efficacy is evidenced by a robust reduction in immunoglobulin G (IgG) anti-dsDNA levels, with markedly improved renal function. The treatment also effectively mitigated immune complex deposition and multiple inflammatory chemokines, including I309, IL-16, and MIP-3. This alleviated kidney damage and suppressed lymphocyte infiltration. We found that CsA alone was ineffective across the analyzed markers, while UA alone produced only a modest effect, highlighting the complementary action of their combination. These findings underscore the potent anti-inflammatory and antioxidant properties of UA and suggest that combining it with CsA offers a more robust strategy for controlling inflammation and preserving renal integrity in LN. Given the FDA-approved status of CsA and UA’s “generally recognized as safe” (GRAS) classification, this combination therapy presents a promising and practical clinical pathway for the treatment of lupus nephritis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Center for Convergent Bioscience and Medicine (CCBM), The University of Alabama, Tuscaloosa, Alabama, 35487, United States.
- Department of Translational Science and Medicine, College of Community Health Sciences, The University of Alabama, Tuscaloosa, Alabama, 35401, United States.
- Alabama Life Research Institute, The University of Alabama, Tuscaloosa, Alabama, 35487, United States.
- Department of Biological Sciences, The University of Alabama, Tuscaloosa , Alabama, 35487, United States.
- Department of Biomedical Engineering, University of Houston, Houston, Texas, 77204, United States.
- Molecular and Cellular Pathology, Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama, 35294, United States.
Förderung
- NIH HHS
- National Institutes of Health
Zitieren
APA
Ganugula, R., Babalola, K. T., Arora, M., Maruvada, V., Pavuluri, A., Karthikeyan, S. K., Chandrashekar, D. S., Varambally, S., Agarwal, S. K., Mohan, C., & Ravi Kumar, M. N. V. (2026). Combined cyclosporine A and urolithin A therapy ameliorates murine lupus nephritis. The Journal of Immunology, 215(4). https://doi.org/10.1093/jimmun/vkag087
Vancouver
Ganugula R, Babalola KT, Arora M, Maruvada V, Pavuluri A, Karthikeyan SK, et al. Combined cyclosporine A and urolithin A therapy ameliorates murine lupus nephritis. The Journal of Immunology. 2026;215(4). doi:10.1093/jimmun/vkag087
BibTeX
@article{Ganugula2026,
author = {Ganugula, R and Babalola, K T and Arora, M and Maruvada, V and Pavuluri, A and Karthikeyan, S K and Chandrashekar, D S and Varambally, S and Agarwal, S K and Mohan, C and Ravi Kumar, M N V},
title = {Combined cyclosporine A and urolithin A therapy ameliorates murine lupus nephritis},
journal = {The Journal of Immunology},
year = {2026},
volume = {215},
number = {4},
doi = {10.1093/jimmun/vkag087}
}
EUVIMED